Fosun Pharma: Controlled subsidiary obtains approval for drug supplement application.

Fosun Pharma announced that the supplemental application for a new indication for Hansol Kang, independently developed by its holding subsidiary Shanghai Fuhong Hanlin Biotechnology Co., Ltd. and its subsidiaries, has been approved by the National Medical Products Administration. The new indication is for the treatment of adult patients with previously untreated diffuse large B-cell lymphoma using the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone. It is also approved for the treatment of relapsed or refractory diffuse large B-cell lymphoma in adults who are not eligible for hematopoietic stem cell transplantation using the combination of bendamustine and rituximab.